STOCKHOLM, April 25 British private equity group
3i is in discussions to sell pharmaceutical company
Xellia which could fetch around 750 million euros ($974.66
million), two sources familiar with the matter said.
The sources said talks were at an advanced stage and that a
deal with a strategic buyer could happen soon. One of the people
said Linklaters was acting as legal adviser to 3i. The sources
declined to be identified because the discussions were private.
A 3i spokesperson was not available for comment. Linklaters
did not immediately return a request for comment.
3i has closed offices, cut staff and prepared asset sales in
an extensive restructuring programme under new CEO Simon Borrows
who took the helm in May last year. It is aiming to reduce debt
to below 1 billion pounds by June, from 1.2 billion at the end
3i has already made several exits this year, including
selling plastic equipment maker Mold-Masters for $963 million.
It is also looking to sell ferry group Scandlines,
which it owns together with Allianz Capital Partners
Xellia is based in Oslo and employs more than 850 people,
with production facilities in Norway, Denmark, Hungary and
China, according to its website. It focuses on anti-infective
treatments and has sales in over 70 countries.
Xellia was created in 2008 when 3i bought NYSE-listed
Alpharma's active pharmaceutical ingredients business for 258